Japan research group uses ethanol to grow heat-tolerant vegetables
The group, led by Seki Motoaki at Riken Center for Sustainable Resource Science, has discovered that plants can grow in high temperatures by feeding ethanol through the roots and spraying the alcohol on leaves.
In an experiment using cherry tomatoes, the researchers applied ethanol, diluted to about 0.1 percent, to the plants and exposed them to heat at 50 degrees Celsius for several hours.
They said they found that the leaves grew larger than those treated only with water and the number of fruits more than tripled.
When ethanol was applied to other plants, the researchers said they detected changes, such as increases in proteins that protect cells from heat and sugar contained in leaves and fruits.
The research group said the findings show that ethanol can effectively bring out plants' ability to grow, even under severe heat.
Seki noted that ethanol is readily available and can be used in a simple way just by diluting it. He expressed hope that his group will further advance studies to make the methods applicable worldwide to help alleviate agriculture problems caused by extreme heat.
Japan has been facing record summer heat, raising agricultural concerns about poor harvests and a decline in quality. The agriculture ministry says continued hot weather could have negative effects on various crops, such as causing cabbage and other leafy vegetables to stop growing and tomato plants to bear no fruit.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Japan Times
19 minutes ago
- Japan Times
Japan gets serious about attracting world-class researchers
Japan's scientific and technological future is at a crossroads. After decades of economic stagnation, a record low birth rate of 1.15 children per woman in 2024 and the fastest-aging society globally — projected to shrink under 100 million within 20 to 30 years — the nation no longer has the number of homegrown researchers needed to compete on the world stage. The good news is the Japanese government has responded with a bold effort to rebuild the nation's scientific and technological competitiveness by recruiting world-class scientists, particularly from the United States. In June, the Cabinet Office launched J-RISE (Japan Research & Innovation for Scientific Excellence), a ¥100 billion ($677 million) package to attract global research talent. J-RISE is a major pillar of the government's broader University for International Research Excellence initiative, which supports top Japanese universities through the national ¥10 trillion University Fund. The fund, managed by the Japan Science and Technology Agency, aims to elevate the global standing of Japanese institutions by supporting world-class research environments. This level of investment signals a clear policy shift: Japan wants to become a global scientific hub. Sadly, this important strategic pivot is taking place against a backdrop of rising nationalist sentiment and economic frustration, neither of which bode well for attracting world-class researchers. Inflation in Japan has surged to 41-year highs, driven in part by a weak yen and rising import costs. While major Japanese firms agreed to the largest wage hikes in decades this year (around 5%), real wages have remained stagnant since the mid-1990s, unlike the 30%-50% gains seen in other Group of Seven nations. Younger generations, in particular, feel left behind — burdened by job insecurity, shrinking pensions and an economic system that hasn't worked for them in over 30 years. This economic disillusionment is fueling political extremes. In the recent Upper House election, the new conservative party, Sanseito, won 14 seats by channeling public frustration on immigration. Sanseito's platform, guided by a 'Japanese First' ideology, calls for further restricting land purchases by non-Japanese and tightening immigration laws — despite the nation's worsening labor shortage. It draws on populist tactics: Its leader, Sohei Kamiya, has explicitly emulated U.S. President Donald Trump's style to channel economic frustration and cultural fear into votes. Yet, according to a 2023 study by an independent think tank, Japan faces a projected shortage of more than 11 million workers by 2040, making foreign labor not optional, but essential. While Sanseito's messaging typically targets foreign land buyers and blue-collar workers, the atmosphere it fosters does not distinguish between different kinds of foreigners. Once xenophobia is normalized, it doesn't stop to distinguish between a factory trainee and a quantum physicist. A scientist considering relocation to Japan may not be the intended target — but the underlying message is loud and clear: 'You are not fully welcome here.' Japan faces serious demographic headwinds. A 2024 Organisation for Economic Co-operation and Development report warns that if current fertility, employment and immigration trends continue, the population could shrink by 45% by 2100 and the labor force by over 50%. In response, public opinion is slowly evolving. A 2024 Asahi Shimbun poll found that 62% of respondents supported increasing foreign workers in labor-shortage sectors — up from 44% in 2018 — with stronger support among seniors. Yet acceptance doesn't always translate to inclusion. Studies from the OECD and other researchers show that many Japanese remain hesitant about immigrants settling permanently or living nearby, even when those immigrants are skilled professionals in essential fields like health care. Cultural and identity-based concerns still act as quiet barriers to true integration. And yet, Japan is entering a global competition to recruit world-class scientific talent — especially, as mentioned earlier, from the United States, where political volatility has shaken researchers' confidence. In response to the Trump administration's proposed severe cuts to U.S. science funding — including plans to slash the National Science Foundation by over 50% and the National Institutes of Health by roughly 40% — several countries, including Germany, France and the U.K., launched targeted initiatives to attract U.S.-based scientists. These efforts addressed growing concerns about unstable funding and politicization of research, offering fast-track visas, generous start-up grants and internationally oriented academic environments. Japan has attempted similar talent recruitment programs in the past, including the World Premier International Research Center Initiative and various Japan Society for the Promotion of Science fellowship programs. But these often fell short due to rigid institutional structures, lack of long-term career pathways, limited English-language support and persistent language barriers — all of which hindered integration for scientists and their families. J-RISE appears to be the most ambitious effort yet, but its success depends on whether Japan can create a truly welcoming research ecosystem. It arrives within the broader context of global competition. And while bold in its funding and goals, it must also confront the same core challenge other countries have faced: Can policy alone attract world-class scientists if the broader society signals ambivalence — or even resistance — toward foreigners? Science doesn't flourish in closed societies. It depends on openness to ideas, to people and to new ways of thinking. World-class scientists choose where to live and work based not just on salary or prestige, but on whether they and their families will feel safe, respected and welcome. Japan's leadership should be commended for its commitment to strengthening scientific excellence. But talent cannot be recruited with money alone. If Japan wants to lead in science and innovation, it must create an ecosystem that matches its ambitions — one that is not only globally competitive, but also socially inclusive. That means not only welcoming foreign scientists, but also fully engaging underrepresented domestic talent — especially women — who have long been overlooked and underutilized in Japan's science and innovation landscape. The stakes are high: Without a cultural shift, even the best-funded policies may fail to secure Japan's future. Yuko Kakazu, an astrophysicist, is a cohort member of the Mansfield Foundation's U.S.-Japan Network for the Future.
Japan Times
2 days ago
- Japan Times
Drugmaker in Japan seeks approval for stem cell treatment for Parkinson's
Sumitomo Pharma said Tuesday it is seeking approval for a Parkinson's disease treatment that transplants stem cells into a patient's brain, following a successful clinical trial. The drugmaker applied to Japanese regulators for manufacturing and marketing authorization aimed at treating patients with advanced Parkinson's disease, it said in a statement. A trial led by Kyoto University researchers indicated that the company's treatment using induced Pluripotent Stem (iPS) cells — which have the potential to develop into any cell in the body — was safe and successful in improving symptoms. The study involved seven Parkinson's patients between 50 and 69 years old, with each receiving a total of either 5 million or 10 million cells implanted on both sides of the brain. The iPS cells from healthy donors were developed into the precursors of dopamine-producing brain cells, which are no longer present in people with Parkinson's disease. The patients were monitored for two years, and no major adverse effects were found, the study said. Four patients showed improvements in symptoms, it said. The trial results were published in Nature in April. Sumitomo Pharma is also carrying out a clinical trial in the United States. Parkinson's disease is a chronic, degenerative neurological disorder that affects the body's motor system, often causing shaking and other difficulties in movement. Worldwide, about 10 million people have the illness, according to the Parkinson's Disease Foundation. Currently available therapies "improve symptoms without slowing or halting the disease progression," the foundation said. iPS cells are created by stimulating mature, already specialized, cells back into a juvenile state — basically cloning without the need for an embryo. The cells can be transformed into a range of different types of cells, and their use is a key sector of medical research.
Japan Times
2 days ago
- Japan Times
Kyoto University team develops pain reliever comparable to morphine
A Kyoto University research team has developed a pain-reliever that is comparable to morphine but does not have serious side effects. Morphine, often administered to cancer patients, has serious adverse effects such as breathing issues and addiction. According to the team, the newly developed drug, Adriana, is a groundbreaking painkiller, which works on a completely different mechanism to morphine and other existing synthetic opioids. The drug has the potential to revolutionize pain control in the medical field, the team said. The team also expects that the drug will help resolve the so-called opioid epidemic, in which a large number of deaths occur mainly due to overdoses of opioids. Its findings were published in the online edition of the U.S. journal Proceedings of the National Academy of Sciences. When a person encounters a life-threatening situation, norepinephrine, an organic chemical secreted from the brain, suppresses pain. For its study, the team focused on the human body regulating oversecretion of norepinephrine. By introducing a new research technology, the team succeeded in developing a drug blocking such a control function for the first time in the world. In a clinical trial conducted at the Kyoto University Hospital between January 2023 and December 2024, the team confirmed the new drug's efficiency to a certain extent for patients including 20 who underwent lung cancer surgery. The team plans to conduct a clinical trial in the United States for 400 postsurgery patients in 2026, aiming to put Adriana into practical use in 2028. "We hope that the new drug will help cancer patients who previously had no choice but to use opioids live their lives without pain as well as a need to worry about addiction or serious side effects," Masatoshi Hagiwara, a professor at the university, said.
